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Within-host models of COVID-19 infection dynamics enable the
merits of different forms of antiviral therapy to be assessed in
individual patients. A stochastic agent-based model of COVID-
19 intracellular dynamics is introduced here, that incorporates
essential steps of the viral life cycle targeted by treatment
options. Integration of model predictions with an intercellular
ODE model of within-host infection dynamics, fitted to patient
data, generates a generic profile of disease progression in
patients that have recovered in the absence of treatment. This
is contrasted with the profiles obtained after variation of model
parameters pertinent to the immune response, such as effector
cell and antibody proliferation rates, mimicking disease
progression in immunocompromised patients. These profiles
are then compared with disease progression in the presence of
antiviral and convalescent plasma therapy against COVID-19
infections. The model reveals that using both therapies in
combination can be very effective in reducing the length of
infection, but these synergistic effects decline with a delayed
treatment start. Conversely, early treatment with either therapy
alone can actually increase the duration of infection, with
infectious virions still present after the decline of other markers
of infection. This suggests that usage of these treatments
should remain carefully controlled in a clinical environment.1. Introduction
COVID-19 is a recently emerging infectious disease caused by severe









































outbreaks of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002, and of Middle East
respiratory syndrome coronavirus (MERS-CoV) in 2012, this is the third outbreak of a coronavirus since
the turn of the century. Mathematical models of COVID-19 transmission at the population level have
been instrumental in controlling the spread of the virus, but a detailed understanding of within-host
infection dynamics is still lacking. Like SARS-CoV and MERS-CoV, SARS-CoV-2 is a betacoronavirus in
Group IV of the Baltimore classification of viruses. Compared with other single-stranded (ss)RNA
viruses, coronaviruses have the longest genomes. The smallest RNA viruses, for example, are only
approximately 1–4 kb in length, and HIV has two copies of an approximately 10 kb genome, while the
SARS-CoV-2 genome is a positive-sense, ssRNA molecule of approximately 30 kb. As a consequence, the
viral life cycle of coronaviruses is distinct from most other ssRNA viruses, and existing intracellular
infection models, e.g. for hepatitis C virus [2], cannot be applied here. Therefore, we introduce here a
novel intracellular model of SARS-CoV-2 infection that incorporates essential steps specific to coronaviral
life cycles. This model enables us to study in detail the viral dynamics inside an infected cell, and
provides a framework to study the impacts of antiviral treatments on the infection dynamics within an
infected cell. In particular, it enables us to quantify the impact of different treatment options on the viral
load that is secreted from an infected cell.
Outcomes from the intracellular model are then integrated into an intercellular model, that takes the
impact of the immune response on infection dynamics within an infected individual into account. The
model has been parametrized with data from 12 patients from a study in Singapore [3], enabling us to
generate a generic profile of disease progression in patients that have recovered from the disease. Model
predictions agree well with experimentally and clinically measured parameters such as the duration of
the incubation period, suggesting that this scenario is representative of disease progression seen in
COVID-19 patients. We then use this model to study the infection dynamics in patients with different
levels of immune responses by varying parameters associated with the immune response, such as the
proliferation rates of effector cells and antibodies, and the rate by which effector cells remove infected
cells. Comparison of different scenarios is based on tissue damage and viral load, highlighting the
impact(s) of antibodies and adaptive cell-mediated immune response on infection dynamics.
This provides a framework in which to compare the impacts of different forms of antiviral therapy and
assess their synergies. We focus here on two prominent forms of therapy against COVID-19: remdesivir,
that inhibits virus production within an infected cell [4], and convalescent plasma (CP) therapy, whereby
CP derived from recently recovered donors is transfused to the patients as an additional support [5].
Recent studies have concluded that remdesivir is an effective antiviral treatment option for COVID-19 [4].
However, the rapid spread and novel nature of the disease make the detailed evaluation of effective
treatment protocols difficult. Using mathematical models enables us to study in detail the effect of the
drug remdesivir on viral load in a COVID-19 infection. Gonçalves et al. used a ‘target-cell limited’ model
to evaluate the efficacy of different treatment options against SARS-CoV-2 infections [6]. They showed that
if drugs such as remdesivir are administered very early, this may help control viral load, but may not have
a major effect in severely ill patients. Iwanami et al. also introduced a mathematical model to describe the
within-host viral dynamics of SARS-CoV-2 and demonstrated that late timing of treatment initiation can
mask the effect of antivirals in clinical studies of COVID-19 [7]. However, none of these models have
included the impact of the immune response directly into their model, which plays an important role in
the outcomes of the infection. In order to analyse different aspects of viral dynamics, studying the
interactions between viruses and the immune system of the host is crucial [8,9]. In this work, we take the
impact of the immune response on infection dynamics into account to perform a more robust analysis of
different treatment options. Regarding the CP therapy, several studies performed in various countries
have shown that this treatment is effective against COVID-19 infections and its safety has been well
established in a randomized clinical trial (RCT) on a large population [5,10–15]. However, finding the
optimal dose and time for CP therapy is still debated [5]. Our intercellular model provides insights into
the effects of different dosages and treatment starts in terms of infection-related quantities for CP therapy
and this supports efforts in combating the COVID-19 pandemic.
2. Results
2.1. An in silico model of intracellular SARS-CoV-2 infection dynamics
Our stochastic model of viral infection dynamics within an infected host cell tracks the different viral and
cellular components required for formation of progeny virus. These include the structural proteins that
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Figure 1. An earlier treatment start, especially during the latent period, is more effective. (a) Illustration of a SARS-CoV-2 virion; the
viral genome (dark green) is in complex with nucleocapsid (N) protein (light green) and is enclosed by the viral envelope that is
studded by other structural glycoproteins, the spike (S) protein (red), the membrane (M) protein (maroon) and the envelope (E)
protein (yellow). (b) Time lag before the release of the first virion from an infected cell; the maximal release of virions occurs when
the replicase–transcriptase complex (RTC) elongation probability, r, is high and the frameshifting rate, q, is between 0.3 and 0.5. (c,
d ) Profiles of viral load from an infected cell after introducing treatment at different times post infection, for a concentration of 25
(c) and 50 (d ) molecules of remdesivir, respectively. The black solid curve indicates the drug-free control. The magenta (long-
dashed), green (dotted), red (dashed-dotted) and orange (dashed) curves correspond to a treatment start at 50, 30, 20 and









































as the nucleocapsid (N) protein (figure 1a). N protein forms a complex with the genomic RNA (gRNA),
and thus aids its compaction for ease of packaging within the viral envelope. The S protein binds the
angiotensin-converting enzyme 2 (ACE-2) receptor on human cells and is therefore essential for cell
entry. The model also includes non-structural proteins that are important for the viral life cycle, such
as the replicase–transcriptase complex (RTC), and keeps track of the numbers of gRNAs (and sub-
genomic sgRNAs) at different stages of the replication process. These include both the original plus-
sense template of the RNA molecules, as well as their negative-sense variants that arise transiently
during transcription. There are nine negative-sense sub-genomic RNAs (–sgRNAs), corresponding to
different gene products. In particular, there is an individual one for each of the structural proteins,
allowing the virus to produce these components in the different quantities required for formation of
viral particles [16].
The reactions modelling viral replication within the host cell are described in detail in the Methods
section and the electronic supplementary material (SI). Here we provide a brief summary of the main
reactions. The SARS-CoV-2 genome encodes two polyproteins, pp1a and pp1ab. The former is
translated from the open reading frame ORF1a, and the latter from the overlapping reading frames 1a









































frequencies of occurrence of the ribosomal frameshift is a key mechanism of self-regulation of protein
expression of the virus and hence an important parameter in our model, which is captured by the
frameshift probability q [18].
Proteins cleaved from pp1a and pp1ab form the RTC, which is then used by the virus for genome
replication and production of the nine (–)sgRNAs. (–)sgRNAs are produced through discontinuous
transcription [19], where elongation of nascent (–)RNA continues until the first functional
transcription-regulating sequence (TRS) is encountered. A fixed proportion of RTCs will disregard the
TRS motif and continue to elongate the nascent strand, while the remainder will halt synthesis of the
nascent minus strand and instead synthesize (–)sgRNAs [20]. The nine TRS motifs in the SARS-CoV-2
genome correspond to the nine sgRNAs produced, hence the choice to elongate or terminate synthesis
occurs up to nine times during the elongation process [21]. The (–)RNA and (–)sgRNAs produce
positive-sense RNAs by recruiting RTC. The sgRNAs are translated to form proteins using cellular
ribosomes. In the final step, a gRNA and the structural proteins (S, M, N and E) form a new virion
according to an assembly reaction that takes the stoichiometry of the different viral components into
account [16], and the virus particle is then released from the host cell.
Stochastic simulations of the reactions were implemented using the Gillespie algorithm [22], and the
number of particles released over the course of 100 h was computed as the average over 200 stochastic
simulations. Parameter values used (electronic supplementary material, table S1) are predominantly
based on experimentally available data [16,21,23–26]; for parameters for which no data were available,
we ensured that our main conclusions are robust against their variation. In particular, the release rate
of virions, following a time lag between infection of a host cell and its first release of viral particles, is
constant and virions are secreted linearly (electronic supplementary material, figure S3).
We note, however, that the length of the time lag, and correspondingly the total number of virions
released, are affected by some of these parameters and therefore warrant a more detailed
investigation. For example, increasing the ribosomal protein production rate (electronic supplementary
material, figure S3a) or the RTC nucleotide association rate (electronic supplementary material, figure
S3b) decreases the time lag and therefore increases the number of virions released. By contrast,
variation of the half-life of RTC or the formation rate of RTC from the constituent proteins does not
have a significant effect on the time lag (electronic supplementary material, figure S3c and d).
Figure 1b shows the time lag to the release of the first virion from an infected cell as a function of the
ribosomal frameshifting probability q and of the RTC elongation probability r.
Figure 1b indicates that decreasing r results in a rapid increase in the time lag: for example, when r =
0.55 and the virus produces many sub-genomic fragments, this time lag is longer than 200 h. This implies
that viral load is maximized for the scenario that the RTC favours continuation of the transcription
process when encountering a TRS. Given the importance of frameshifting in the coronavirus life cycle
to control the relative numbers of different viral components, it has been argued that the virus will
have evolved to optimize this ratio. In particular, frameshift signals have been characterized
experimentally previously to have efficiencies in the range of 20–45% [27–30], although a recent study
has suggested that the frameshift rate may be slightly higher [31]. Our model identifies an optimal
value of 0.3 < q < 0.5 as the range with the lowest time lag and hence maximal virion release (figure 1b),
in good agreement with the experimentally determined range of 20–45%.
2.2. The intracellular infection model in the presence and absence of antiviral therapy
In order to assess the impact of an antiviral drug on viral load in the context of the intracellular model,
we use the example of remdesivir, which is a widely used treatment option against COVID-19.
Remdesivir, originally developed as a treatment for hepatitis C virus and later trialled for efficacy
against Ebola, acts as a nucleoside analogue that mimics adenosine nucleotide [32]. During the
replication process, RTC may insert remdesivir molecules instead of adenosine, resulting in capping of
the strand and thus terminating replication [25]. We have included additional reactions into the model
that describe remdesivir binding to the RTC complexes on the gRNAs and sgRNAs to capture this
(see electronic supplementary material for details), and track the effect of a given, fixed number of
remdesivir molecules per cell on the release of viral particles from an infected host cell.
Figure 1c,d shows the impact on viral load released from a single-infected cell for two different
concentrations of remdesivir, as well as treatment starts at different times post infection (TPIs). In figure
1c, a free concentration equivalent to 25 remdesivir molecules per cell is considered, corresponding to a
concentration of approximately 0.06 μM (see electronic supplementary material) [26]. The black solid









































stochastic simulations of the model. Magenta (long-dashed), green (dotted), red (dashed-dotted) and
orange (dashed) curves show the impact(s) of treatment start at TPIs of 50, 30, 20 and 10 h, respectively.
Figure 1c demonstrates that starting treatment during the latent period reduces the total number of
virions released significantly. Even given a later treatment start the rate of virion production is slowed
down, but the earlier treatment is started, the stronger the reduction in the virion production rate. Our
results are consistent with experiments that probed the impact of remdesivir on mouse hepatitis virus
(MHV) infection [33], which also revealed that starting treatment earlier and during the latent period is
more effective, as is the case also in other betacoronaviruses. Figure 1d shows the impact of doubling
the drug concentration (equivalent to a concentration of 50 molecules of remdesivir per cell). In this
case, starting treatment early during infection at 20 h post infection reduced the number of virions
released on average by more than half. However, starting treatment later in the infection, such as 30 or
50 h post infection, decreases the number of released virions by a smaller fraction. This suggests that
although an increased drug concentration can be beneficial, starting the treatment earlier is more
effective at reducing viral load than an increase in dosage.
The intracellular model provides new insights into the release of viral particles from an infected cell,
both in the absence and presence of antiviral treatment. The model shows that there is a time lag between
infection of a host cell and the first release of new virions. It also shows that virions are effectively
released linearly in time after the time lag which is not observed in other viral infections such as
hepatitis B viral (HBV) infection [34]. The model reveals that antiviral therapy based on remdesivir
has a higher efficacy in infected cells which are in the latent period compared with those that are
already producing virions. We incorporated these facts in the next section into an intercellular model
of within-host infection dynamics. The model can be used as a platform for comparing different
therapeutic strategies that may develop in the future against COVID-19 infections [34].2.3. Within-host model of SARS-CoV-2 infection dynamics
The intracellular model affords insights into the release of viral particles from an infected cell, both in the
absence and presence of antiviral treatment. We integrate results from this model into an intercellular
model of within-host infection dynamics in order to probe the impact of the adaptive immune
response on disease progression both in the absence and presence of antiviral therapy. Uninfected
target cells (T) are assumed to follow logistic growth with proliferation rate rT and carrying capacity
Tm. Inclusion of growth capacity of uninfected cells is important, because SARS-CoV-2 is detectable in
patients over 20 days after the onset of symptoms [35], comparable to the time taken to regenerate the
epithelium (up to one month [36]). Uninfected cells are infected by free virions at rate β. Although
infected cells in the latent phase probably die at a somewhat lower rate than productively infectious
cells, we assume that all infected cells die at approximately the same rate, δ, in order to minimize the
number of free parameters that would complicate parameter estimation.
Our intracellular model shows a time lag between infection of a host cell and the first release of new
virions, consistent with experimental observation [16]. This effect is included into our intercellular model
via a latent phase (L) with a lifetime defined as 1/γ, where γ denotes the average transition rate from the
latent to the productively infectious (I) state, i.e. when the cell sheds viral particles. The intracellular
model also shows that virions are effectively released linearly in time. Therefore, we model infected
cells as producing new virions V at a constant production rate p, and assume that they are naturally
cleared at rate c.
Our model of the adaptive immune response consists of antibodies A (humoral immune response)
that remove virions at rate k, and effector cells E (cell-mediated immune response) that kill infected
cells at rate μ, assuming the same rate for cells in the latent and infectious phase in order to minimize
the number of free parameters. Antibodies are produced at rate pA proportional to the viral load and
are degraded at rate dA. After viral clearance, the antibody level is kept at a homeostatic level, because
of the long-lived plasma and memory B cells. To represent this, we add a logistic term with
proliferation rate rA and carrying capacity Am to the antibody equation. A fixed basal level of effector
cells is assumed (λE/dE), and upon infection the population of effector cells will expand at rate α(L +
I )E [37–39]. Both L and I have an impact on the immune response, because infected cells during the
latent phase are producing viral proteins. Although infected cells at different stages of infection are
likely to express slightly different levels of viral peptide-MHC (major histocompatibility complex) on
their surface, we assumed that the rates are the same for L and I in order to minimize the number of



















Figure 2. Diagram of the model of immune response to a viral infection. Purple circles show host cells (uninfected cells, infected
cells in latent phase and productively infected cells), green circles indicated immune response (effector cells and free antibodies) and
grey shows virions. Double arrow-headed lines show natural clearance. Bar-headed lines indicate the removal of infected cells and









































Considering the above assumptions, the model, as illustrated in figure 2, takes on the following form:
dT
dt





¼ bTV  dL gL mLE,
dI
dt
¼ gL dI  mIE,
dV
dt
¼ pI  cV  kAV,
dE
dt
¼ lE þ aðLþ IÞE dEE,
dA
dt
¼ pAV þ rAA 1 AAm
 
 kAV  dAA:
ð2:1Þ
Themodelwas fitted to data from 12 hospitalized patients in Singapore [3] usingmeasurements of viral
load (see Methods). The parameter values derived from fitting V are presented in table 1. Our model
captures essential features of the viral load in all patients, including the positions and heights of the first
peak, and where applicable also those of the second peak (see electronic supplementary material, figure
S4). In all patients, the viral load eventually decreases to below detectable levels, matching the clinical
outcomes in these patients. We note that even details such as the slower viral decline in patients 2 and
12 are correctly represented by our model.
Our model predicts an incubation period, i.e. time between infection and presentation of symptoms, of
4.25 days (3.45–5.05 95% CI), in excellent agreement with the median SARS-CoV-2 incubation period of
roughly 5 days estimated based on clinical data elsewhere [16,40]. The average time after which
antibodies appear is predicted here to be 16 days (13.9–18.1 95% CI) after infection, again in excellent
agreement with the clinically reported first detection of antibodies after 10–20 days [16]. Similarly, the
latent period of 27.28 h (26.19–28.37 95% CI) predicted by our model agrees well with the
experimentally observed latent period of 12–36 h [41].2.4. Immune response dynamics
The within-host model enables the roles of different aspects of the adaptive immune response in viral
clearance to be investigated in more detail. The adaptive immune response to a viral infection relies
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Figure 3. Antiviral treatment prevents the second viral peak and an earlier antiviral treatment start is more effective. Solid lines
indicate progression of the infection in the absence of treatment as a control. Dashed, dotted and dash-dotted curves show the result
of starting treatment at 7, 6 and 5 days post infection (dpi), respectively. Parameters are the median values of table 1 (black curves
(a–c)). Red curves (d–f ) correspond to the scenario of low removal rate of infected cells by effector cells (μ = 3.5 × 10−4). Blue
curves (g–i) illustrate the scenario of a low proliferation rate of effector cells (α = 5.4 × 10−10), and magenta curves ( j–l) of a low
antibody proliferation rate (rA = 1). The green line (horizontal line in (b), (e), (h) and (k)) indicates the viral detection limit. Note









































clearance, we first generate a generic progression profile based on the data from all 12 patients, and then
vary parameters pertinent to different aspects of the immune response in isolation in order to probe their
impact on disease progression.
The median values from our parameter fitting were used to generate a generic progression profile
from the 12 patient data as a control (black curves in figure 3a–c and electronic supplementary
material, figure S5). This control curve reveals a characteristic two-peak behaviour for viral load
(figure 3b), with antibodies passing the detection limit (0:1 ngml1 ¼ 4 108 molecules ml−1 [42])
after 14 days post infection (electronic supplementary material, figure S5d).
The cell-mediated immune response is captured in the equations by two factors: μ, the removal rate of
infected cells by effector cells (T cells); and α, the proliferation rate of the effector cells. As λE/dE is the
basal level of effector cells, it is assumed to be constant for each patient [37]. Thus, α and μ are
parameters that are probably varying in different patients. In particular, they would be expected to be
lower in immunocompromised patients than for a patient with a healthy immune system [37,39,43,44].
Figure 3d (red curve; see also electronic supplementary material, figure S5) demonstrates that although
reduction in the value of μ can increase the damage to healthy cells (T) slightly, this effect is much
stronger when reducing α (figure 3g, blue curves). Even though decreasing either of these parameters
causes a slower decline in viral load after the second peak (figure 3e,h), a smaller value of α in
addition increases the maximum of both peaks. Figure 3j,k,l (magenta curves in electronic
supplementary material, figure S5) model the case where just the humoral immune response is
weakened, i.e. where the proliferation rate of antibodies rA is reduced [42]. In this case, viral load
shows three peaks, and the damage to healthy cells recovers only slowly. This demonstrates that each
component of the immune response plays a different, and crucial role in the recovery process. In







































this could lead to significant tissue damage, with infections lasting much longer than for non-
immunocompromised patients.oyalsocietypublishing.org/journal/rsos
R.Soc.Open
Sci.8:2100822.5. The impact of different therapeutic strategies on viral dynamics in patients with different
types of immune response
In order to study the effects of antiviral therapy in the context of our intercellular model, we multiply the
viral production rate p by (1− e), where 0≤ e≤ 1 is the drug efficacy [39,43,45,46]. As our intracellular
model (figure 1c,d ) suggests that starting treatment in the latent period is most effective, and would
effectively block the production of virions, we set γ = 0 at the onset of treatment. This means that
infected cells in the latent phase (L) do not transition to phase I, and begin shedding virions at a
reduced rate (following a time lag τ) compared with cells that were already in phase I at the onset of
treatment. However, as our numerical results show that the delayed model (electronic supplementary
material, figure S6) has the same behaviour as the model without a time delay, i.e. τ = 0, (figure 3), we
set τ = 0. Thus, we have the following equations for the numbers of infected cells and free virions:
dL
dt
¼ bTV  dL gð1 uðt tRÞÞL mLE,
dI
dt
¼ gð1 uðt tRÞÞL dI  mIE,
dV
dt
¼ pð1 eÞuðt tRÞLþ pð1 huðt tRÞÞI  cV  kAV,
ð2:2Þ
where θ(.) is the Heaviside function (uðtÞ ¼ 1 for t  0, and θ(t) = 0 for t < 0), and tR is the time when the
antiviral treatment (remdesivir) is introduced. Cells in phase L produce virions at the reduced rate of
p(1− e). Our intracellular model (figure 1c,d ) suggests that starting therapy during the latent period can
reduce the level of virions released by approximately 99% on average. We thus assume e = 0.99 for the
efficacy of remdesivir in cells in phase L. This is a good approximation, as all values of e calculated
from figure 1c are above 98%, regardless of treatment start time. Cells that were already in the
productively infectious phase (I) at the time of treatment start are assumed to produce virions at rate
p(1− η), where η≤ e is the efficacy of remdesivir in these cells. Figure 1c indicates that starting therapy
during the productively infectious period can reduce the level of released virions by approximately
90% on average. Therefore, we set η = 0.9. We note that these values of e and η are consistent with
values used in previous models [6,7,21].
Figure 3a–c illustrates the impact of treatment on viral clearance in a patient who would most likely
recover without treatment, as the parameters have been chosen as the median values of the 12 patients
who have recovered from COVID-19 without treatment (table 1). In this generic scenario, a treatment
start 7 days post infection (dpi), which is approximately the time of the first peak in viral load,
prevents the second peak from occurring (black dashed lines in figure 3). An earlier treatment start at
6 dpi also leads to the same result. However, starting treatment even earlier at 5 dpi (black dash-dot
lines in figure 3) also reduces the damage to healthy cells. Even though free virus declines slower in
this case, the area under the viral load curve (AUC), an infection-related quantity commonly used to
help the assessment of a treatment against acute viral diseases [47], is much smaller. In respiratory
infections, even after viral clearance the immune response can cause respiratory and systemic
symptoms in some incidences [47,48]. A treatment start at 5 dpi results in a reduction in the peak of
immune response cells, suggesting that early treatment perhaps could mitigate against this.
In figure 3, solid red (figure 3d–f ), blue (figure 3g–i) and magenta (figure 3j–l ) curves indicate cases
where different aspects of the immune response are weakened in isolation. In particular, the solid red
(figure 3d–f ) curves illustrate the case of a reduction in the removal rate of infected cells by effector
cells μ by 99% with respect to the generic case (μ = 3.5 × 10−4), the solid blue (figure 3g–i) curves that
of a 92% reduced proliferation rate of effector cells α (α = 5.4 × 10−10), and the solid magenta (figure
3j–l ) curves correspond to a low antibody proliferation rate (rA = 1 instead of 1.98). As in the generic
case above, figure 3d–l indicate that in each case starting treatment 5 dpi reduces tissue damage, viral
peak height and AUC significantly (electronic supplementary material, table S2), compared with
treatment starts at 6 or 7 dpi, again emphasizing the importance of an early treatment start. However,
early treatment increases the duration of infection compared with a later therapy start (figure 3h). This









































Our intercellular model also enables the modelling of drugs that operate at the level of the immune
response, rather than virus production in the intracellular milieu. As an example of a therapy option of
this type, we study the impact of CP therapy on viral dynamics [5]. For this, we add a new variable to our
model ( ~A), which captures the antibodies that are administered as treatment. We assume that these
antibodies remove virions at rate kf, where 0≤ f≤ 1, implying that they are at most as efficient as the
antibodies that are being developed by the body over the course of the infection. The equations for
the number of virions and antibodies thus have the form
dV
dt
¼ pI  cV  kAV  uðt tCPÞkf~AV,
d ~A
dt
¼ uðt tCPÞðkf ~AV  dA ~AÞ,
ð2:3Þ
where ~AðtÞ ¼ 0 for t < tCP and ~AðtCPÞ ¼ ~Am, with ~Am representing the number of antibodies per ml that
are administered as treatment. tCP denotes the time at with the treatment is started, and θ(.) is the
Heaviside function.
Our model enables the impact of CP therapy on viral dynamics to be studied for different treatment
starts and doses, thus addressing the bottle-neck pointed out in the recent literature of finding the
optimal dose and start for CP treatment [5]. Using again median values from table 1 to generate a
generic patient profile as a control, and using three immunocompromised cases that are presented in
figure 3 (red, blue and magenta curves, representing cases with reduced values for the immune
response parameters μ, α and rA, respectively) we studied the impact of CP therapy. Electronic
supplementary material, figure S7 shows the minimum level of therapeutic antibodies ~Am that is
needed to reduce the AUC by 25% and 50% as a function of the start of treatment (in dpi) and the
factor f by which therapeutic antibodies are less efficient than those produced by the host during the
infection. It indicates that the level of ~Am that is needed for an effective reduction in the AUC is at
most around 3 1011 molecules ml−1. This is in good agreement with clinical data, reporting a 200 ml
dose of CP and Am ¼ 4 1012 molecules ml−1 (see Methods) [5,42,49]. Indeed, this implies that each
dose would contain about 8 1014 molecules, resulting in ~Am ¼ 2:6 1011 molecules ml−1 on the basis
of an average level of 3 l blood in the body [50]. Hence, a reduction of the AUC by 50% is achievable.
Electronic supplementary material, figure S7 also shows that AUC reduction is comparable in the
range 0.7≤ f≤ 0.9, therefore, we use the average value of this range (f = 0.8) in our calculations. Our
conclusions are robust for efficiencies greater than or equal to 0.15, while for values of f below 0.15
the outcomes vary for different immunocompromised cases. Using these parameters, we present a
comparative analysis between antiviral and CP therapy and explore their synergistic potential.
Figure 4 shows that similar to the case of antiviral therapy in figure 3, an early treatment start is more
effective in the reduction of tissue damage and the level of AUC compared with a later therapy start (cf.
electronic supplementary material, figure S8 for the equivalent of figure 3 for CP therapy; cf. electronic
supplementary material, table S3 for AUC values). While figure 3 reveals scenarios in which an antiviral
therapy does not mitigate against tissue damage (such as a later treatment start at 6 or 7 dpi), figure 4
shows that using CP therapy can reduce tissue damage even for those delayed treatment starts.
Interestingly, figure 4 shows that starting CP therapy early can increase the duration of infection more
than for antiviral therapy, implying that for an early treatment start using remdesivir is more effective.
By contrast, for later treatment starts CP therapy reduces the viral load faster and decreases tissue
damage compared with remdesivir therapy. Our model also enables us to probe the synergies of these
treatments options. Figure 4c,f,i and l indicate that for an early treatment, combination therapy
mitigates against a longer duration of the infection (cf. electronic supplementary material, table S4 for
AUC values). However, for later treatment starts any synergistic effects are minimal and combination
therapy has the same outcome as CP therapy in isolation. Thus, unless infection is detected early, e.g.
though an efficient track and trace system, treatment would probably start at a time when CP therapy
in isolation would be as effective as combination therapy.
Figure 5 indicates the impact of starting treatments after the onset of symptoms, i.e. the day on which
symptoms were first reported by the 12 patients in the study [3] used for model fitting. Both treatments
reduced the duration of the infection significantly (in 67% of the patients), enabling a faster recovery, or
otherwise have no significant impact on the duration of the infection. However, in some cases in which
the peak in viral load and the AUC are significantly reduced (electronic supplementary material, table
S5), the treatments have not decreased the duration of infection. This figure also shows that there are
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Figure 4. An early CP therapy increases the duration of infection more compared with an early antiviral therapy. Solid lines indicate
progression of the infection in the absence of treatment as a control. Dashed, dotted and dash-dotted curves show the result of starting
treatment at 7, 6 and 5 dpi, respectively. Parameters are the median values of table 1 (black curves (a–c)). Red curves (d–f ) correspond
to the scenario of low removal rate of infected cells by effector cells (μ = 3.5 × 10−4). Blue curves (g–i) illustrate the scenario of a low
proliferation rate of effector cells (α = 5.4 × 10−10), and magenta curves ( j–l ) of a low antibody proliferation rate (rA = 1). The green
line (horizontal line in (b), (c) (e), ( f ), (h), (i), (k) and (l )) indicates the viral detection limit. First and second columns indicate the









































combination therapy of both treatments. In the other cases, these treatment options have more or less
similar effects, although CP therapy performs slightly better, and in these cases there is not a notable
synergistic effect.3. Discussion
The severe consequences of the COVID-19 pandemic demand a concerted interdisciplinary effort to
identify novel antiviral solutions. Vaccination options against SARS-CoV-2 are actively pursued and a
number of treatments are now in use in the clinics, but there are still many open questions regarding
when and how best to administer these treatments, either in isolation or in combination. Whilst
modelling of disease transmission has already played a key role in informing policy makers [51],
models of within-host dynamics have not yet had a prominent role in combating the disease. There is
a precedence of intracellular modelling for other viral diseases, such as hepatitis C virus [2]. However,
such models cannot be readily transferred to coronaviral infection, as viral life cycles are very
different. Here we introduce a within-host model of a SARS-CoV-2 infection that contains sufficient
details specific to coronaviruses to enable antiviral strategies against SARS-CoV-2 to be compared and
to analyse their synergies. We demonstrate this via a comparative analysis of an antiviral treatment
(remdesivir) and CP therapy, which apart from steriod treatment are the most prominent forms of
therapy currently used against COVID-19 infections. In particular, we compare disease progression for
different treatment starts and dosages, and thus provide new insights into these therapeutic options.
Our analysis highlights, as expected and previously observed [6,7], that an early treatment start
before the first peak in viral load can reduce both tissue damage and the peak viral load, especially
when using a combination of both therapies. However, those models do not capture the impact of
early treatment on the duration of the infection. Surprisingly, our model suggests that early treatment
by either form of therapy alone can actually increase the duration of infection compared with a later
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Figure 5. Starting treatment after the onset of symptoms reduces the peak in viral load and leads to faster viral clearance. Solid
lines indicate the best fit to patient data. Dashed and dotted curves indicate the result of starting antiviral and CP therapy after the









































therapy start, probably because suppressing virus production results in a reduced immune response. This
implies that even though early treatment accelerates the recovery process and reduces the peak in viral
load, the infection may persist for a longer time than for later treatment starts, meaning that these
patients may possibly still be infectious.
Our model has provided insights into disease progression for different doses and treatment starts for
the CP therapy [5]. In particular, it enabled us to address a question recently raised in the literature as to
the impact of dose and time of treatment on disease progression under CP treatment [5]. Our model also
enabled us to perform a comparison between the antiviral treatment and CP therapy, and explore their
potential synergistic effects. The model reveals that early into the infection an antiviral treatment using
remdesivir could be more effective than CP therapy, and a combination therapy can significantly reduce
the duration of infection. However, for later treatment starts, CP therapy appears to be more beneficial
than antiviral therapy, and there are no longer any significant synergistic effects that would warrant
combination therapy. These insights from our within-host model suggest that the time course of
infection should be considered when deciding on an appropriate therapeutic response to a COVID-19
infection.4. Methods
4.1. Intracellular modelling of SARS-CoV-2 infection
The first step in the viral lifecycle is the production of two polyproteins (pp1a and pp1ab) using the host
cell ribosomes. The kinetics of ribosomes in vivo are studied using insights from a detailed stochastic
model [52]. For synthesis of the polyproteins pp1a and pp1ab, host ribosomes (denoted by R in
electronic supplementary material, figure S1b) reversibly bind to (+)RNA with binding/unbinding













































We model the kinetic steps involved in ribosome initiation and transition to the elongation state (Ri1a:
(+)RNA) that occur subsequent to ribosomal binding to the ( + )RNA to produce pp1a as a single
kinetic step with rate rin.
R : ðþÞRNA!rin Ri1a : ðþÞRNA:
The ribosome then translates the pp1a gene (ORF1a) at rate t1a. After translation of the pp1a gene, the
ribosome can either frameshift −1 nt to the ORF1b reading frame, translating the polyprotein pp1ab,
or terminate, releasing the polyprotein pp1a [18]. We model the −1 ribosomal frameshift as a reaction
with rate q × tf and the termination at ORF1a as a reaction with rate (1− q)tf. If the ribosome
successfully frameshifts, it completes translation of the ORF1b reading frame with rate t1b, terminates,
and releases the polyprotein pp1ab







Ri1b :ðþÞRNA!t1b pp1abþ Rþ (+)RNA:
The polyproteins pp1a and pp1ab form RTC at rate frt
pp1aþ pp1ab!frt RTC:
The transcription of gRNA which leads to the formation of –gRNA and nine –sgRNAs is modelled
as illustrated in the electronic supplementary material, figure S2. RTC (denoted by RTC in the






The full-length genome contains functional transcription-regulating sequence (TRS) motifs which are
found at the 30 end of the leader (leader TRS) and in front of each of the nine ORFs (electronic
supplementary material, figure S1a) [20]. During transcription of the full-length minus strand by the
RTC, the process can terminate at one of these TRS motifs, resulting in one of the nine negative
sgRNA being produced. In our model, when an RTC encounters TRS motif number k, it will continue
the elongation of the negative strand with rate r × tc, and terminate with rate (1− r)tc, resulting in the
production of (−)sgRNAk
RT0 :ðþÞRNA!rtin RTi1 :ðþÞRNA,
RTik :ðþÞRNA!trk RTk :ðþÞRNA,
RTk :ðþÞRNA!
ð1rÞtc ðÞsgRNAk þ RTCþ (+) RNA,
RTk :ðþÞRNA!rtc RTikþ1 :ðþÞRNA,
RTi10 :ðþÞRNA!t10 ðÞRNAþ RTCþ (+) RNA:
Here, trk is the rate of RTC transcription between the TRS at site k− 1 and site k (electronic
supplementary material, figure S2) and each ðÞsgRNAk for k = 1, 2, …, 9, corresponds to sgRNAs
for N, 8, 7b, 7a, 6, M, E, 3a, S (−)sgRNAs, respectively, whereas the k = 10 state with transcription
rate t10 denotes the rate to transcribe the remaining length of 22 kb of RNA upstream of the
structural genes. This last step is responsible for the creation of full-length (−)RNA. Then
(−)sgRNAs and (−)RNA serve as templates for (+)sgRNAs and viral genome synthesis, respectively.
The negative RNAs bind to RTC and produce positive RNAs (electronic supplementary material,
equation S1).
(+)sgRNA1, (+)sgRNA6, (+)sgRNA7 and (+)sgRNA9 encode structural proteins N, M, E and S,







































are at an equilibrium level, where +sgRNAs are saturated with available ribosomes and produce protein
at constant rates tn, tm etc.
(+) sgRNA1!
tn (+) sgRNA1 þN,
(+) sgRNA6!
tm (+) sgRNA6 þM,
(+) sgRNA7!
te (+) sgRNA7 þ E,
(+) sgRNA9!
ts (+) sgRNA9 þ S:
The budding of a virion is modelled as a single reaction with budding rate kbud as follows [2,16]:
(+) RNAþ 300Sþ 2000Mþ 1000Nþ 100E!kbud virion:R.Soc.Open
Sci.8:2100824.2. Modelling of antiviral strategy
Remdesivir acts as a nucleoside analogue that mimics the adenosine structure [32]. During the replication
process, RTC may insert remdesivir molecules rather than adenine, which caps the strand and stops the
replication process at rate rterm [25]. In order to model the impact of this drug, we assume that complexes
with RTC in our model can bind (and subsequently unbind from) remdesivir molecules (Rem). Thus, the
reactions have the following form:




Re: RTik :ðþÞRNA!rterm RTC,




Re: RTi10 :ðþÞRNA!rterm RTC,




Re: RTk :ðþÞRNA!rterm RTC,
where k = 1, 2, …, 9.
4.3. Patient data
Our patient data comprise the first 18 confirmed patients who reported COVID-19 infection in Singapore
[3]. Nasopharyngeal swabs were collected for up to 30 days since onset of symptoms. Five patients
received lopinavir–ritonavir treatment, and in one patient viral load was detectable only twice, and
these six patients were therefore excluded from the analysis. The viral loads were reported in cycle
threshold (Ct) values, which is inversely proportional to the logarithm of the viral RNA copy number
(logðVÞ ¼ 0:3231Ctþ 14:11) [35]. We converted Ct values to viral copies per millilitre. In model
fitting, viral load values under the detection threshold were set at the detection limit (Ct = 38).
4.4. Intercellular model parameter estimation
COVID-19 is a respiratory illness, so we assume that modelling insights from influenza models are
applicable. In influenza, at approximately 5–7 dpi mitoses are detected at the basal cell layer, and
regeneration of the epithelium begins. Complete resolution of the epithelial takes up to one month
[36]. We therefore assume that the maximum proliferation rate for uninfected cells is small, and that
rT ¼ 0:1 d1. The number of host cells that express ACE-2 and transmembrane serine protease
(TMPRSS) is approximately equal to 1011 (Tm = 10
11) [16], and we use T(0) = Tm. As SARS-CoV-2 is a
novel infection, we assume that E(0) = 0 and that the basal level of effector cells is low (λE = 1 and
dE ¼ 0:5d1) [53]. However, considering a higher basal level does not change model outcomes









































infected cells by effector cells, are estimated using viral load data fitting. Note that increasing λ and
decreasing μ simultaneously does result in the same viral dynamics, although it will change the value of
the peak in effector cells. Since data are only available regarding viral load, we decided to fix the basal
level of effector cells before finding other parameters [42,53]. Initially, there is no specific antibody,
therefore A(0) = 0 and dA ¼ 0:033 d1 [42]. We use 1 μg ml−1 immunoglobulin G (IgG) positive control as
a strong positive standard [49]. Thus, we assume Am ¼ 1mgml1 ¼ 4 1012 molecules ml−1. Although
we are setting the individual’s antibody carrying capacity to a fixed value [42], we also checked that
variation of the parameter does not impact the qualitative results and therefore all conclusions remain
valid. dA is measured for HBV infection, but it has been shown that rAA(1−A/Am)− dAA is equivalent
to a logistic growth of antibodies with growth rate ρA = rA− dA [42]. Since we are fitting rA, fixing dA
does not have a significant impact on the model. The same argument is valid for dE, and as we are
assuming a fixed basal level (λE/dE), changing dE would not have a significant effect on our results.
The patient data used is only available from the time after onset of symptoms, and the initial viral
load at the start of the infection is not recorded. We therefore estimate the value V(0) assuming the
infection is transmitted via droplets. The average number of expelled droplets during talking is
assumed to be 1000 [54,55]. It has also been reported that more than 50% of droplets have a size
range between 50 and 75 μm [55]. Thus, the average volume in expelled droplets during talking is
equal to 1:1 104 ml. The median level of viral load on the day of symptom onset in patients in this
study is estimated as 5 103 virion ml−1 [56]. We assume that infected individuals infect others before
the onset of symptoms, and we therefore assume an average level of 103 virion ml−1 are available for
transmission. Thus, assuming Vð0Þ ¼ 0:1 virion ml−1 appears to be a reasonable choice [6]. This value
is also comparable to those used in modelling of influenza [57].
Since structural identifiability is a necessary condition for model fitting, we used the method by
Castro & de Boer [58] to show that our model (2.1) is structurally identifiable (see electronic
supplementary material, section S3 for more detail). We estimate the remaining parameters and the
incubation period (the time between the beginning of the infection and the onset of symptoms) by
fitting V from the model (2.1) to patient data individually in Matlab using the method in Ciupe et al.
[42] which uses the minimum search function for data fitting. Although we fitted patient data
individually, which is suboptimal compared to population fitting using mixed effects, the outcomes of
the model were in agreement with clinically measured values, such as the incubation period and
the onset of appearance of antibodies in the body. The resulting parameter values are presented in
table 1. Decreasing/increasing of V(0) (Vð0Þ ¼ 0:01 virion ml−1 or Vð0Þ ¼ 1 virion ml−1) does not
change the estimated values of parameters significantly and only changes the estimated incubation
period by ±1 day. Additionally, we used residual bootstrapping to provide 95% confidence intervals
(CIs) for the parameter estimates following [37] (electronic supplementary material, table S2). For each
set of patient data fV1,V2, . . . ,Vng, we calculated the normalised residuals ei ¼ Vi=Vi,i ¼ 1,2, . . . ,n,
where fV1,V2, . . . ,Vng denotes the viral load values predicted by the model. We then created the set
fV1,V2,:::,Vng where Vi ¼ Vi  ej for ej randomly chosen to be any of the normalised residuals or 1,
the latter to include the option that the data remains unchanged. We created 50 samples and fitted
each individually to the data. We then calculated the 95% CI for each given parameter across the 50
parameter sets (electronic supplementary material, table S2). We generated 500 simulations based on
randomly chosen parameters from the 50 parameter sets, and then used these curves to calculate the
95% CI for each patient (see red shaded areas in electronic supplementary material, figure S4). As the
95% CIs have negligible width compared with the widths of the curves, given the logarithmic scale,
we also added the mean plus/minus standard deviation as shaded green areas in order to reflect the
noise in the data, especially for P4 and P6. We note that the predicted two-peak behaviour is
consistent with observations in Wölfel et al. [59], and indeed is expected in any model that includes
the adaptive immune response [60].
Data accessibility. The code and information on the data used are available at the Dryad Digital Repository https://doi.
org/10.5061/dryad.sn02v6x38 [61].
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